Articles

Poll

Podcasts

Slideshows

Videos

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Alpha-gal syndrome remains vastly underdiagnosed, with expanding tick geography and delayed reactions complicating recognition across specialties.

Alpha-Gal Syndrome: Closing an Underrecognized Allergy Diagnostic Gap 

FDA actions, a WAO consensus update, and late-stage trial data in food allergy, anaphylaxis, CRSwNP, and EoE, all in this August 2026 recap.

7 Allergy Headlines You Missed in August 2026

Mahboobeh Mahdavinia, MD, says a published, safe at-home protocol for resolving egg allergy is rarely used because of the counseling time it demands.

Egg Ladder Protocol Remains Underused Despite Safety Data

Mahboobeh Mahdavinia, MD, says annual follow-up, not initial specialist access, is the missing piece in food allergy resolution disparities.

Closing the Food Allergy Resolution Gap Needs More Than Specialist Access

Mahboobeh Mahdavinia, MD, says racial gaps in food allergy resolution reflect access to care, not biology.

Racial Gap in Food Allergy Resolution Traced to Access, Not Biology

Mahboobeh Mahdavinia, MD, PhD, discusses new FORWARD data showing peanut and shellfish allergies resolve far less often than milk, soy, or wheat.

Socioeconomic, Racial Disparities Linked to Food Allergy Resolution

IMPACT-PLuS investigator Jennifer A. Dantzer says predictive biomarkers and formal remission testing remain unanswered questions in peanut OIT.

Peanut OIT Follow-Up Study Highlights Gaps in Allergy Remission Research

IMPACT-PLuS follow-up data show 35% of children treated with peanut OIT had a reaction years later, with 5 requiring epinephrine, Jennifer Dantzer, MD, says.

IMPACT-PLuS Data Show Low but Real Reaction Risk with Peanut OIT

IMPACT-PLuS follow-up found 80% of children treated with early-life peanut oral immunotherapy remained peanut tolerant 8 to 11 years later.

Early-Life Peanut OIT’s Decade-Long Benefit, With Jennifer Dantzer, MD

Brian Vickery, MD, discusses the mechanism, dose-escalation design, and outlook for a first-in-human microneedle immunotherapy trial for peanut allergy.